Machine signal
Active cluster sell — 3 distinct insiders, $2.1M, window ends Jul 8, 2026.
Figures computed from official regulatory filings — .
Analysttarget 37.55 USD (+113%) · consensus 4.83/5 · 12 buy · 0 hold · 0 sell
Ownershipinsiders 1.69% · institutions 126.12% · short 23.5% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Syndax Pharmaceuticals Inc only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
16 buys114 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Metzger Michael A | Exercise | $206.6K | SEC |
| Metzger Michael A | Sell | $784.8K | SEC |
| Metzger Michael A | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Botwood Nicholas A.J. | Exercise | $311.2K | SEC |
| Botwood Nicholas A.J. | Exercise | $431.7K | SEC |
| Botwood Nicholas A.J. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Botwood Nicholas A.J. | Sell | $566.6K | SEC |
| Botwood Nicholas A.J. | Sell | $617K | SEC |
| Botwood Nicholas A.J. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Goldan Keith A. | Sell | $22.4K | SEC |
| Metzger Michael A | Sell | $130K | SEC |
| Goldan Keith A. | Sell | $71.7K | Unusual size | SEC |
| Metzger Michael A | Sell | $360.9K | SEC |
| Huber Martin H. Jr. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Goldan Keith A. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Metzger Michael A | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Legault Pierre | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Metzger Michael A | AwardD (derivative) | $9M | Unusual size | SEC |
| Goldan Keith A. | AwardD (derivative) | $2.4M | SEC |
| Goldan Keith A. | Sell | $42.9K | SEC |
| Metzger Michael A | Sell | $152.8K | SEC |
| Goldan Keith A. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Metzger Michael A | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Katkin Keithtrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Jarrett Jennifer | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |